Talk to the Veterans Crisis Line now
U.S. flag
An official website of the United States government
Veterans Benefits and Health Care About VA Find a VA Location

VA Health Systems Research

Go to the VA ORD website
Go to the QUERI website

HSR&D Citation Abstract

Search | Search by Center | Search by Source | Keywords in Title

Life Goals Collaborative Care for patients with bipolar disorder and cardiovascular disease risk.

Kilbourne AM, Goodrich DE, Lai Z, Clogston J, Waxmonsky J, Bauer MS. Life Goals Collaborative Care for patients with bipolar disorder and cardiovascular disease risk. Psychiatric services (Washington, D.C.). 2012 Dec 1; 63(12):1234-8.

Dimensions for VA is a web-based tool available to VA staff that enables detailed searches of published research and research projects.

If you have VA-Intranet access, click here for more information vaww.hsrd.research.va.gov/dimensions/

VA staff not currently on the VA network can access Dimensions by registering for an account using their VA email address.    Search Dimensions for VA for this citation
* Don't have VA-internal network access or a VA email address? Try searching the free-to-the-public version of Dimensions


Abstract:

OBJECTIVE: This pilot study compared Life Goals Collaborative Care (LGCC) with enhanced treatment as usual in reducing cardiometabolic risk factors and improving outcomes for persons with bipolar disorder. METHODS: Participants were randomly assigned to LGCC (N = 34) or enhanced treatment as usual (N = 34). LGCC included four weekly self-management sessions and monthly telephone contacts for six months thereafter. Enhanced treatment as usual included wellness mailings. Outcomes were blood pressure, body mass index (BMI), quality of life, functioning, and symptoms. RESULTS: Compared with enhanced treatment as usual, LGCC was not associated with reductions in cardiometabolic risk factors in 12-month repeated-measures analyses. Among patients with a BMI of 30 or systolic blood pressure of 140, LGCC was associated with improvements in functioning (beta = -2.2 and beta = -3.8, respectively, p = .04) and reduced depressive symptoms (beta = -2.0 and -3.5, respectively, p = .04). CONCLUSIONS: Further research is needed to determine whether LGCC improves outcomes for patients with elevated cardiometabolic risk.




Questions about the HSR website? Email the Web Team

Any health information on this website is strictly for informational purposes and is not intended as medical advice. It should not be used to diagnose or treat any condition.